Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Cancer drug imatinib tested for rare eye melanoma – but trial stops early

NCT ID NCT00421317

Disease control Sponsor: Centre Oscar Lambret Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tested the drug imatinib in 13 adults with metastatic ocular melanoma, a rare eye cancer that has spread. The goal was to see if imatinib could stop tumor growth for at least 3 months. The trial was terminated early, so the results are limited and it is unclear if imatinib helps patients with this condition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Imatinib
What this could lead to
If it works, this could point toward a treatment option for metastatic ocular melanoma, a rare and hard-to-treat cancer.
What could go wrong
This trial was terminated early and enrolled only 13 people, so results are very limited. Imatinib may not shrink tumors or improve survival, and it can cause side effects like fatigue, nausea, and liver problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

13 people

The number who actually took part.

Started

Dec 2005

Finished

Nov 2009

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Metastatic ocular melanoma * Age \> or = 18 years old * Measurable metastases \> or = 10 mm according to RECIST criteria * PS-WHO \< or = 1 or IK \> 70 percent * Normal hepatic function * PNN \> 1500/mm3, platelets \> or = 100 000/mm3 * Contraception * Informed consent signed Exclusion Criteria: * Patient with two prior lines of systemic treatment (chemotherapy, immunotherapy or association) * Other evolutive neoplasic disease * Severe hepatic insufficiency * Severe renal insufficiency * Somatic or psychiatric co-morbidity incompatible with the protocol * Leptomeningeal or cerebral metastatic dissemination * Pregnant or lactating woman * Other antitumoral treatment * Patient participating to another clinical trial with an experimental drug * Known hypersensitivity to Imatinib or one of its excipients * Resecable single metastasis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Melanoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

melanoma ocular melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Melanoma

Contacts and locations

Locations

  • Centre Francois Baclesse

    Caen, 14076, France

  • Centre Georges-Francois Leclerc

    Dijon, 21079, France

  • Centre Gustave Roussy

    Villejuif, 94805, France

  • Centre Hospitalier Regional Universitaire

    Lille, 59035, France

  • Centre Jean Perrin

    Clermont-Ferrand, 63011, France

  • Centre Leon Berard

    Lyon, 69373, France

  • Centre Oscar Lambret

    Lille, 59020, France

  • Centre Paul Strauss

    Strasbourg, 67065, France

  • Centre Val d'Aurelle Paul Lamarque

    Montpellier, 34298, France

  • Hopital Universitaire de Hautepierre

    Strasbourg, 67098, France

  • Institut Claudius Regaud

    Toulouse, 31052, France

  • Institut Curie

    Paris, 75248, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.